EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5

Ye Yang, Sydney Smith, Yan Q Chen, Hongxia Li, Eugene Y Zhen, John H Sloan, Robert W Siegel, Yuewei Qian, Yi Wen, Hyesoo Jung, Julia L Scheithauer, Sander Kersten und 2 weitere

Journal of Lipid Research · 2026

DOI: 10.1016/j.jlr.2026.101050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2026. Verfasst von Ye Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; Department of Medicine, University of California, Los Angeles, Los Angeles…. Hauptthemen laut MEDLINE: Fenofibrate, Angiopoietins, Apolipoproteins A, Hypolipidemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Leducq, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fenofibrate and other fibrates are peroxisome proliferator-activated receptor alpha agonists that are used to lower plasma triglyceride (TG) levels. Although fibrates are effective in decreasing TG, their ability to reduce adverse cardiovascular events and cardiovascular mortality in clinical trials has been disappointing. Peroxisome proliferator-activated receptor alpha agonists influence the expression of dozens of genes, but the mechanisms by which they lower TG levels are incompletely understood. Apolipoprotein A5 (APOA5) and angiopoietin-like proteins 3, 4, and 8 (ANGPTL3/4/8) are important regulators of intravascular TG metabolism. To explore if their regulation might explain the TG-lowering effect of fibrates, we examined the impact of fenofibrate on the expression of APOA5 and the ANGPTL3/4/8 proteins in mice and humans. In WT mice, fenofibrate reduced plasma TG levels, increased Angptl4 and Angptl3 transcripts in the liver, and reduced Angptl8 and Apoa5 transcripts. Fenofibrate also decreased plasma APOA5 levels and increased levels of ANGPTL3, ANGPTL3/8, ANGPTL4/8, and the C-terminal domain of ANGPTL4 (CD-ANGPTL4). These changes would be predicted to increase rather than decrease TG levels. The TG reduction by fenofibrate was maintained in Apoa5-deficient mice, further indicating that APOA5 is not involved in TG lowering by fenofibrate. In humans, fenofibrate reduced TG without increasing APOA5 levels or reducing ANGPTL3/8 levels. In addition, fenofibrate treatment increased levels of ANGPTL3, ANGPTL4/8, and CD-ANGPTL4. The collective human and mouse data suggest that APOA5 and ANGPTL3/4/8 proteins do not mediate fenofibrate-induced TG lowering. Our findings are noteworthy because elevated levels of ANGPTL3, ANGPTL4/8, and CD-ANGPTL4 are associated with increased cardiovascular mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenofibrateAngiopoietinsApolipoproteins AHypolipidemic AgentsPeptide HormonesAnimalsHumansAngiopoietin-like ProteinsApolipoprotein A-VMiceAngiopoietin-Like Protein 3Angiopoietin-Like Protein 8Angiopoietin-Like Protein 4TriglyceridesMaleLiverGene Expression RegulationMice, Inbred C57BLMice, Knockout

Stichwörter der Autor:innen

ANGPTL3ANGPTL3/8ANGPTL4/8APOA5CD-ANGPTL4fenofibrate

Substanzen

FenofibrateAngiopoietin-like ProteinsApolipoprotein A-VAngiopoietin-Like Protein 3AngiopoietinsAngiopoietin-Like Protein 8Angiopoietin-Like Protein 4Apolipoproteins AAngptl3 protein, mouseANGPTL8 protein, human

Autor:innen und Institutionen

  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, University of California, Los…
  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
  • Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition and Health, Wageningen University, The Netherlands; Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA. Electronic address: ahk4@…
  • Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: sgyoung@mednet.ucla.edu.
  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: konrad_robert@lilly.com.

Förderung

  • Fondation Leducq
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Yang, Y., Smith, S., Chen, Y. Q., Li, H., Zhen, E. Y., Sloan, J. H., Siegel, R. W., Qian, Y., Wen, Y., Jung, H., Scheithauer, J. L., Kersten, S., Young, S. G., & Konrad, R. J. (2026). Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2026.101050

Vancouver

Yang Y, Smith S, Chen YQ, Li H, Zhen EY, Sloan JH, et al. Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5. Journal of Lipid Research. 2026. doi:10.1016/j.jlr.2026.101050

BibTeX
@article{Yang2026,
  author = {Yang, Ye and Smith, Sydney and Chen, Yan Q and Li, Hongxia and Zhen, Eugene Y and Sloan, John H and Siegel, Robert W and Qian, Yuewei and Wen, Yi and Jung, Hyesoo and Scheithauer, Julia L and Kersten, Sander and Young, Stephen G and Konrad, Robert J},
  title = {Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5},
  journal = {Journal of Lipid Research},
  year = {2026},
  doi = {10.1016/j.jlr.2026.101050}
}
Kostenlos starten →